MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided here...
Saved in:
Main Authors | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Format | Patent |
Language | English French |
Published |
26.11.2020
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Antibody-drug conjugates that bind to human oncology targets are disclosed. The antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety. The disclosure further relates to methods and compositions for use in the treatment of cancers by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods of making same are also disclosed.
L'invention concerne des conjugués anticorps-médicament qui se lient à des cibles en oncologie humaine. Ces conjugués anticorps-médicament comprennent une fraction médicamenteuse inhibitrice de Mcl-1. L'invention concerne en outre des procédés et des compositions destinés à être utilisés dans le traitement de cancers par l'administration des conjugués anticorps-médicament décrits. L'invention concerne également des conjugués lieur-médicament comprenant une fraction médicamenteuse inhibitrice de Mcl-1 et des procédés de préparation de ceux-ci. |
---|---|
Bibliography: | Application Number: CA20203138058 |